These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

848 related items for PubMed ID: 28937990

  • 1. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
    Ozaki Y, Koide M, Furuya Y, Ninomiya T, Yasuda H, Nakamura M, Kobayashi Y, Takahashi N, Yoshinari N, Udagawa N.
    PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
    [Abstract] [Full Text] [Related]

  • 2. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, Tsuda E.
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [Abstract] [Full Text] [Related]

  • 3. The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study.
    Kato G, Shimizu Y, Arai Y, Suzuki N, Sugamori Y, Maeda M, Takahashi M, Tamura Y, Wakabayashi N, Murali R, Ono T, Ohya K, Mise-Omata S, Aoki K.
    Arthritis Res Ther; 2015 Sep 12; 17(1):251. PubMed ID: 26373710
    [Abstract] [Full Text] [Related]

  • 4. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.
    Bone; 2011 Dec 12; 49(6):1290-8. PubMed ID: 21925296
    [Abstract] [Full Text] [Related]

  • 5. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S, Liu XS, Zhou G, Li Z, Luk KD, Guo XE, Lu WW.
    J Bone Miner Res; 2011 Jun 12; 26(6):1272-82. PubMed ID: 21611968
    [Abstract] [Full Text] [Related]

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep 12; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss: comparison with RANKL-overexpressing transgenic male mice.
    Koide M, Kobayashi Y, Ninomiya T, Nakamura M, Yasuda H, Arai Y, Okahashi N, Yoshinari N, Takahashi N, Udagawa N.
    Endocrinology; 2013 Feb 12; 154(2):773-82. PubMed ID: 23291450
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X, Xing J, Long CL, Peng Q, Humphrey MB.
    J Bone Miner Res; 2017 Nov 12; 32(11):2207-2218. PubMed ID: 28650106
    [Abstract] [Full Text] [Related]

  • 10. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 11. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L, Jung JU, Wu H, Xia WF, Pan JX, Shen C, Mei L, Xiong WC.
    Proc Natl Acad Sci U S A; 2015 Mar 17; 112(11):3487-92. PubMed ID: 25733894
    [Abstract] [Full Text] [Related]

  • 12. GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast differentiation.
    Amirhosseini M, Madsen RV, Escott KJ, Bostrom MP, Ross FP, Fahlgren A.
    J Cell Physiol; 2018 Mar 17; 233(3):2398-2408. PubMed ID: 28731198
    [Abstract] [Full Text] [Related]

  • 13. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity.
    Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida K, Yasuda H.
    J Biol Chem; 2013 Feb 22; 288(8):5562-71. PubMed ID: 23319583
    [Abstract] [Full Text] [Related]

  • 14. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Endocrinology; 2005 Apr 22; 146(4):1991-8. PubMed ID: 15618359
    [Abstract] [Full Text] [Related]

  • 15. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
    Sasaki T.
    Microsc Res Tech; 2003 Aug 15; 61(6):483-95. PubMed ID: 12879416
    [Abstract] [Full Text] [Related]

  • 16. Effects of novel lactoferrin peptides on LPS-induced alveolar bone destruction in a rat model.
    Yamada S, Chea C, Furusho H, Oda K, Shiba F, Tanimoto K, Tate SI, Miyauchi M, Takata T.
    Chem Biol Drug Des; 2024 Jul 15; 104(1):e14574. PubMed ID: 38958121
    [Abstract] [Full Text] [Related]

  • 17. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y.
    Bone; 2007 Aug 15; 41(2):165-74. PubMed ID: 17560185
    [Abstract] [Full Text] [Related]

  • 18. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N.
    Endocrinology; 2006 Jul 15; 147(7):3366-74. PubMed ID: 16627581
    [Abstract] [Full Text] [Related]

  • 19. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W, Shi Y, Lee WC, Lee SY, Long F.
    Bone; 2016 Apr 15; 85():1-8. PubMed ID: 26780446
    [Abstract] [Full Text] [Related]

  • 20. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
    Suzuki T, Suda N, Ohyama K.
    J Bone Miner Metab; 2004 Apr 15; 22(3):185-91. PubMed ID: 15108059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.